Octreotide Protocol: Complete Cycling & Dosing Guide

Octreotide Protocol: Complete Cycling & Dosing Guide

Overview

Octreotide is a synthetic somatostatin analog with clinical applications spanning hormone-secreting tumors, acromegaly, carcinoid syndrome, and variceal bleeding. As a peptide medication available via injection, it works by binding to somatostatin receptors (primarily SSTR2 and SSTR5) on target cells, suppressing growth hormone, insulin, glucagon, and various gastrointestinal hormones through inhibitory G-protein signaling.

For performance and body composition purposes, octreotide's primary mechanism of interest is insulin suppression, which produces moderate evidence (Tier 3) for fat loss: approximately 3.19 kg body weight and 5.92 kg fat mass reduction versus placebo based on meta-analysis of randomized controlled trials. This effect occurs without significant lean body mass loss, making it distinct from catabolic interventions.

Critical context: Octreotide is prescription-only in all jurisdictions and requires medical supervision due to effects on glucose regulation, cardiac conduction, and gallbladder function. This guide is educational only and does not constitute medical advice.

Standard Protocol

The clinical standard for octreotide injection is 100–600 mcg divided into 2–3 daily doses. For body composition and metabolic goals, most practitioners operate within the lower-to-middle range of this spectrum.

Standard dosing architecture:

• Initiation dose: 100 mcg twice daily (200 mcg total daily)
• Maintenance dose: 150–300 mcg twice daily (300–600 mcg total daily)
• Advanced dose: 300 mcg three times daily (900 mcg total daily)

Cycle structure for non-clinical use:

• On-cycle duration: 8–12 weeks
• Off-cycle duration: 4–8 weeks (minimum)
• Frequency of use: Not recommended for continuous year-round use; follow 8–12 weeks on / 6–8 weeks off pattern

The longer off-cycle period (compared to traditional anabolic steroids) is necessary because octreotide's effects on glucose homeostasis, gallbladder function, and cardiac conduction require recovery time. Extended use without breaks increases risk of cholelithiasis (gallstone formation) and metabolic dysregulation.

Goal-Specific Protocols

Fat Loss Protocol (Primary Evidence Base)

Objective: Maximize insulin suppression to reduce fat mass while preserving lean tissue.

Dosing:

• Weeks 1–2: 100 mcg twice daily (200 mcg/day)
• Weeks 3–8: 150 mcg twice daily (300 mcg/day)
• Weeks 9–12: 200 mcg twice daily (400 mcg/day)

Cycle length: 10–12 weeks Off-cycle: 6–8 weeks minimum

Rationale: Gradual escalation minimizes gastrointestinal side effects (nausea, diarrhea) which are most pronounced in weeks 1–2. The meta-analytic evidence supporting fat loss used doses in the 150–300 mcg twice daily range across 6–24 week durations.

Expected fat loss: 3–6 kg over 10–12 weeks, assuming adequate caloric deficit and resistance training. The compound's effect is synergistic with hypocaloric diet; it does not independently create weight loss.

Monitoring requirements:

• Fasting blood glucose before, week 4, and week 8 (risk of hypoglycemia)
• Baseline and week 12 lipid panel
• Gallbladder ultrasound at baseline and end of cycle (screen for stones)
• Blood pressure and heart rate at baseline, week 4, week 8

Hormonal Balance Protocol (Acromegaly/TSH-Secreting Tumors)

Objective: Suppress excess hormone secretion in diagnosed hormone-secreting tumors.

Dosing:

• Starting: 100 mcg three times daily (300 mcg/day)
• Maintenance: 200–300 mcg three times daily (600–900 mcg/day)
• Maximum: Up to 1,500 mcg/day in divided doses (clinical studies)

Cycle length: Typically continuous (not cycled) for tumor suppression; however, this is condition-dependent and requires endocrinologist oversight.

Monitoring: Bi-weekly hormone levels (GH, IGF-1, TSH, free T4) for first 4 weeks; monthly thereafter. Dose adjustment based on hormone suppression targets, not arbitrary timing.

Gut Health Protocol (Bleeding, Pancreatitis)

Objective: Manage variceal bleeding, pancreatic inflammation, or chronic diarrhea/malabsorption.

Dosing (acute bleeding):

• Bolus: 100 mcg IV or subcutaneous
• Continuous infusion: 25–50 mcg/hour for 5 days, then transition to 100 mcg twice daily subcutaneous

Dosing (chronic conditions):

• 100–150 mcg twice daily (200–300 mcg/day)

Cycle structure: Typically 6–8 weeks acute use; off 4 weeks; reassess.

Monitoring: Clinical response (bleeding episodes, stool consistency, abdominal pain); no mandatory lab work beyond routine metabolics.

How to Administer Step-by-Step

Subcutaneous Injection (Most Common Route)

Materials needed:

• Sterile needle (27–29 gauge, 0.5–1 inch)
• Sterile syringe (1 mL)
• Alcohol prep pads
• Vial of octreotide (usually 1 mL containing 100–500 mcg, depending on concentration)
• Sharps disposal container

Reconstitution (if powder formulation):

1. Withdraw appropriate volume of sterile saline or bacteriostatic water into syringe
2. Inject into octreotide vial slowly to avoid foaming
3. Roll vial gently between palms for 30 seconds (do not shake vigorously)
4. Allow to stand for 1–2 minutes
5. Withdraw calculated dose into fresh sterile syringe
6. Use immediately; do not store reconstituted solution longer than 24 hours at room temperature

Pre-filled vials or solution:

• Simply draw calculated dose into sterile syringe; no reconstitution needed

Injection technique:

1. Inspect skin at injection site (abdomen, outer thigh, back of arm) for signs of infection or lipodystrophy
2. Rotate sites to avoid lipoatrophy and injection-site pain
3. Cleanse skin with alcohol pad using circular motion; allow to dry 30 seconds
4. Pinch skin fold gently; insert needle at 45–90 degree angle
5. Inject slowly over 2–3 seconds
6. Withdraw needle and apply gentle pressure with alcohol pad for 10 seconds
7. Dispose of needle in sharps container immediately

Frequency: Typically twice daily (morning and evening); maintain 12-hour separation between doses.

Intramuscular Injection (Less Common, Usually Long-Acting Formulation)

• Use 22–25 gauge needle, 1–1.5 inches
• Inject into gluteal muscle, vastus lateralis, or deltoid
• Inject slowly over 10–15 seconds
• Long-acting formulations (octreotide LAR, lanreotide) typically dosed monthly; follow manufacturer's instructions

Storage

• Unopened vials: Refrigerate at 2–8°C (35–46°F); protect from light
• Opened vials: Refrigerate; use within 14 days of first puncture
• Reconstituted solutions: Use within 24 hours; refrigerate if not used immediately
• Never freeze; frozen octreotide loses potency
• Transport: Use insulated container with ice packs if traveling; maintain cold chain

Cycle Example: 12-Week Fat Loss Protocol

Off-cycle (Weeks 13–20): 8-week complete break; no octreotide.

What to Expect: Timeline of Effects

Days 1–3 (Acute Phase)

• Nausea, mild dizziness, possible diarrhea
• Appetite suppression begins immediately
• Fasting blood glucose may drop 10–20 mg/dL
• Injection site pain, redness, possible induration at 12–24 hours

Week 1

• GI side effects peak; most patients report nausea for 3–5 days, then stabilization
• Appetite suppression pronounced and consistent
• Energy levels may dip slightly; fatigue reported in ~50% of users
• Fasting glucose continues trending downward

Weeks 2–4

• GI tolerance improves significantly in most users
• Appetite suppression remains strong; portion sizes naturally reduce
• Insulin secretion suppressed, reducing postprandial glucose spikes
• Weight loss becomes apparent (typically 1–2 kg in first 2–3 weeks)

Weeks 5–8 (Plateau Zone)

• Appetite suppression plateaus; tolerance complete
• Fat loss continues at steady 0.5–1 kg per week (depending on diet, training)
• Mild bradycardia possible (heart rate reduction of 5–10 bpm)
• Injection site reactions decrease with rotation and technique refinement

Weeks 9–12 (Late Cycle)

• Fat loss may decelerate as body adapts; dose escalation can restart weight loss
• Some users report mood flatness or mild depression (not documented in trials, anecdotal)
• Gallbladder-related discomfort possible if predisposed (rare in short cycles)
• Fasting glucose stabilizes at lower level; hypoglycemia risk increases if eating inadequately

Post-Cycle (Weeks 13+)

• Appetite returns to baseline within 3–7 days
• Blood glucose normalizes quickly (usually 5–10 days)
• No rebound weight gain typical if caloric intake normalized gradually
• Energy rebounds to baseline

Common Protocol Mistakes

1. Insufficient GI Preparation Octreotide causes nausea and diarrhea in 60–80% of users, especially weeks 1–2. Mistake: starting at full maintenance dose. Solution: start at 100 mcg twice daily; advance weekly. Take doses with food; use anti-emetics (ondansetron 4 mg or ginger supplements) preemptively.

2. Ignoring Glucose Monitoring Suppressing both insulin and glucagon can create unpredictable blood glucose dynamics. Mistake: assuming stable glucose response. Solution: check fasting glucose at baseline, week 4, week 8; adjust carbohydrate intake if fasting glucose drops below 70 mg/dL.

3. Inadequate Off-Cycles Octreotide's long-term effects on gallbladder contractility and thyroid function require recovery time. Mistake: continuous use beyond 12 weeks without breaks. Solution: strictly adhere to 8–12 weeks on / 6–8 weeks off. Use off-cycle to reassess metabolic health and conduct monitoring.

4. Injection Site Neglect Repeated injections at same site cause lipodystrophy, induration, and absorption variability. Mistake: injecting in one area repeatedly. Solution: maintain rotation schedule (abdomen quadrants, thighs, back of arms); document sites in log.

5. Skipping Baseline and Cycle Monitoring Without baseline labs, it's impossible to quantify benefit or detect adverse metabolic effects. Mistake: no blood work. Solution: minimum at baseline—fasting glucose, lipid panel, liver function, TSH, baseline ultrasound for gallbladder. Repeat glucose check at weeks 4 and 8.

6. Improper Dose Timing Splitting 300 mcg into single afternoon dose instead of 150 mcg twice daily creates uneven suppression and increased side effects. Mistake: irregular dosing. Solution: set phone reminders; maintain 12-hour spacing between doses.

7. Inadequate Caloric Deficit Octreotide suppresses appetite and insulin, but does not independently cause fat loss without hypocaloric diet. Mistake: expecting fat loss without dietary change. Solution: maintain 300–500 kcal deficit; track intake; octreotide amplifies the effect of existing deficit.

How to Stack with Other Compounds

Stacking with GLP-1 Receptor Agonists (Semaglutide, Tirzepatide) Octreotide + GLP-1 creates dual suppression of insulin secretion and glucagon, plus appetite suppression via different mechanisms. Caution: synergistic hypoglycemia risk. Protocol: reduce octreotide dose to 100 mcg twice daily when adding GLP-1 analog; monitor glucose more frequently (weekly). GLP-1 agents have longer duration, so offset timing by 6+ hours if possible.

Stacking with Metformin Octreotide suppresses insulin; metformin improves insulin sensitivity. Mechanistically complementary. Protocol: standard octreotide dosing (100–300 mcg twice daily) combined with metformin 500 mg twice daily. No dose adjustment required; glucose should remain stable or trend slightly lower. Monitor baseline glucose; metformin may reduce hypoglycemia risk.

Stacking with Thyroid Hormones (T3, T4) Octreotide may suppress TSH and alter thyroid function. Caution: do not use unless TSH/free T4 monitored. Protocol: if stacking, check baseline TSH and free T4; measure every 4 weeks. Increase thyroid hormone dose by 12.5–25% if on octreotide to compensate for potential suppression. Coordinate with prescribing physician.

Stacking with Growth Hormone (Exogenous) Octreotide suppresses endogenous GH; exogenous GH creates antagonism. Not recommended for simultaneous use unless under clinical supervision for specific tumor-related indications. If used together, GH doses must be higher to overcome octreotide suppression.

Stacking with Testosterone or Androgens Octreotide may suppress testosterone via gonadal suppression (animal/observational evidence). Protocol: if combining, monitor baseline and weekly total testosterone. Consider increasing testosterone dose by 10–15% to compensate. Keep doses moderate (TRT ranges, not supraphysiologic).

Stacking with Selective Estrogen Receptor Modulators (SERMs) or Aromatase Inhibitors No direct interaction. Protocol: standard dosing of both; no adjustment necessary. Monitor estradiol if stacking with AI due to potential indirect effects via insulin suppression.

Protocol Quick Reference Table